Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults

The effects of growth hormone (GH) replacement on plasma lecithin:cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP), factors involved in high density lipoprotein (HDL) metabolism, are unknown. We carried out a 6 months study in 24...

Full description

Bibliographic Details
Main Authors: John A.M. Beentjes, Arie van Tol, Wim J. Sluiter, Robin P.F. Dullaart
Format: Article
Language:English
Published: Elsevier 2000-06-01
Series:Journal of Lipid Research
Subjects:
HDL
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520320344
id doaj-0b0ea828bd7e416cb46fd25389c193f3
record_format Article
spelling doaj-0b0ea828bd7e416cb46fd25389c193f32021-04-27T04:41:48ZengElsevierJournal of Lipid Research0022-22752000-06-01416925932Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adultsJohn A.M. Beentjes0Arie van Tol1Wim J. Sluiter2Robin P.F. Dullaart3Department of Endocrinology, University Hospital Groningen, The NetherlandsDepartment of Biochemistry, Cardiovascular Research Institute (COEUR), Erasmus University Rotterdam, The NetherlandsDepartment of Endocrinology, University Hospital Groningen, The NetherlandsTo whom correspondence should be addressed; Department of Endocrinology, University Hospital Groningen, The NetherlandsThe effects of growth hormone (GH) replacement on plasma lecithin:cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP), factors involved in high density lipoprotein (HDL) metabolism, are unknown. We carried out a 6 months study in 24 GH-deficient adults who were randomized to placebo (n = 8), low dose GH (1 U daily, n = 8), and high dose GH (2 U daily, n = 8), followed by a 6 months open extension study with high dose GH (1 dropout). No significant changes in plasma lipoproteins, LCAT, CETP, and PLTP activities, cholesterol esterification (EST) and cholesteryl ester transfer (CET) were observed after placebo. After 6 months of GH (combined data, n = 24), very low + low density lipoprotein (VLDL + LDL) cholesterol (P < 0.05) and apolipoprotein B (P < 0.05) decreased, whereas HDL cholesterol and HDL cholesteryl ester increased (P < 0.05). Prolonged treatment showed comparable effects. Plasma apolipoprotein A-I and Lp[a] remained unchanged. Plasma LCAT (P < 0.01) and CETP activities (P < 0.01), as well as EST (P < 0.01) and CET decreased (P < 0.01) after 12 months of GH (n = 15), but PLTP activity did not significantly change. Changes in EST and CET after 12 months of treatment were independently related to changes in plasma LCAT (P = 0.001 and CETP activity (P = 0.01).In conclusion, GH replacement therapy improves the lipoprotein profile in GH-deficient adults. Chronic GH replacement lowers plasma LCAT and CETP activities, contributing to a decrease in cholesterol esterification and cholesteryl ester transfer. These effects may have consequences for HDL metabolism and reverse cholesterol transport.http://www.sciencedirect.com/science/article/pii/S0022227520320344growth hormone deficiencygrowth hormone replacementHDLLCATCETPPLTP
collection DOAJ
language English
format Article
sources DOAJ
author John A.M. Beentjes
Arie van Tol
Wim J. Sluiter
Robin P.F. Dullaart
spellingShingle John A.M. Beentjes
Arie van Tol
Wim J. Sluiter
Robin P.F. Dullaart
Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
Journal of Lipid Research
growth hormone deficiency
growth hormone replacement
HDL
LCAT
CETP
PLTP
author_facet John A.M. Beentjes
Arie van Tol
Wim J. Sluiter
Robin P.F. Dullaart
author_sort John A.M. Beentjes
title Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
title_short Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
title_full Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
title_fullStr Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
title_full_unstemmed Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
title_sort effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2000-06-01
description The effects of growth hormone (GH) replacement on plasma lecithin:cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP), factors involved in high density lipoprotein (HDL) metabolism, are unknown. We carried out a 6 months study in 24 GH-deficient adults who were randomized to placebo (n = 8), low dose GH (1 U daily, n = 8), and high dose GH (2 U daily, n = 8), followed by a 6 months open extension study with high dose GH (1 dropout). No significant changes in plasma lipoproteins, LCAT, CETP, and PLTP activities, cholesterol esterification (EST) and cholesteryl ester transfer (CET) were observed after placebo. After 6 months of GH (combined data, n = 24), very low + low density lipoprotein (VLDL + LDL) cholesterol (P < 0.05) and apolipoprotein B (P < 0.05) decreased, whereas HDL cholesterol and HDL cholesteryl ester increased (P < 0.05). Prolonged treatment showed comparable effects. Plasma apolipoprotein A-I and Lp[a] remained unchanged. Plasma LCAT (P < 0.01) and CETP activities (P < 0.01), as well as EST (P < 0.01) and CET decreased (P < 0.01) after 12 months of GH (n = 15), but PLTP activity did not significantly change. Changes in EST and CET after 12 months of treatment were independently related to changes in plasma LCAT (P = 0.001 and CETP activity (P = 0.01).In conclusion, GH replacement therapy improves the lipoprotein profile in GH-deficient adults. Chronic GH replacement lowers plasma LCAT and CETP activities, contributing to a decrease in cholesterol esterification and cholesteryl ester transfer. These effects may have consequences for HDL metabolism and reverse cholesterol transport.
topic growth hormone deficiency
growth hormone replacement
HDL
LCAT
CETP
PLTP
url http://www.sciencedirect.com/science/article/pii/S0022227520320344
work_keys_str_mv AT johnambeentjes effectofgrowthhormonereplacementtherapyonplasmalecithincholesterolacyltransferaseandlipidtransferproteinactivitiesingrowthhormonedeficientadults
AT arievantol effectofgrowthhormonereplacementtherapyonplasmalecithincholesterolacyltransferaseandlipidtransferproteinactivitiesingrowthhormonedeficientadults
AT wimjsluiter effectofgrowthhormonereplacementtherapyonplasmalecithincholesterolacyltransferaseandlipidtransferproteinactivitiesingrowthhormonedeficientadults
AT robinpfdullaart effectofgrowthhormonereplacementtherapyonplasmalecithincholesterolacyltransferaseandlipidtransferproteinactivitiesingrowthhormonedeficientadults
_version_ 1721506757996445696